Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit by Jones, Rupert CM et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Respiratory Research
Open Access Research
Accuracy of diagnostic registers and management of chronic 
obstructive pulmonary disease: the Devon primary care audit
Rupert CM Jones*1, Maria Dickson-Spillmann1, Martin JC Mather2, 
Dawn Marks2 and Bryanie S Shackell1
Address: 1Respiratory Research Unit, Peninsula Medical School, 1 Davy Road, Plymouth, UK and 2The Waterside Practice, St. Brannocks Road, 
Ilfracombe, UK
Email: Rupert CM Jones* - rupert.jones@pms.ac.uk; Maria Dickson-Spillmann - maria.spillmann@googlemail.com; 
Martin JC Mather - mjcmather@doctors.org.uk; Dawn Marks - john@brannoc.co.uk; Bryanie S Shackell - bryanie.shackell@pms.ac.uk
* Corresponding author    
Abstract
Background: Guidelines on COPD diagnosis and management encourage primary care physicians to
detect the disease at an early stage and to treat patients according to their condition and needs. Problems
in guideline implementation include difficulties in diagnosis, using spirometry and the disputed role of
reversibility testing. These lead to inaccurate diagnostic registers and inadequacy of administered
treatments. This study represents an audit of COPD diagnosis and management in primary care practices
in Devon.
Methods: Six hundred and thirty two patients on COPD registers in primary care practices were seen
by a visiting Respiratory Specialist Nurse. Diagnoses were made according to the NICE guidelines.
Reversibility testing was carried out either routinely or based on clinical indication in two sub-samples.
Dyspnoea was assessed. Data were entered into a novel IT-based software which computed guideline-
based treatment recommendations. Current and recommended treatments were compared.
Results: Five hundred and eighty patients had spirometry. Diagnoses of COPD were confirmed in 422
patients (73%). Thirty nine patients were identified as asthma only, 94 had normal spirometry, 23 were
restrictive and 2 had a cardiac disorder. Reversibility testing changed diagnosis of 11% of patients with
airflow obstruction, and severity grading in 18%. Three quarters of patients with COPD had been offered
practical help with smoking cessation. Short and long-acting anticholinergics and long acting beta-2 agonists
had been under-prescribed; in 15–18% of patients they were indicated but not received. Inhaled steroids
had been over-prescribed (recommended in 17%; taken by 60%), whereas only 4% of patients with a
chronic productive cough were receiving mucolytics. Pulmonary rehabilitation was not available in some
areas and was under-used in other areas.
Conclusion:  Diagnostic registers of COPD in primary care contain mistakes leading to inaccurate
prevalence estimates and inappropriate treatment decisions. Use of pre-bronchodilator readings for
diagnosis overestimates the prevalence and severity in a significant minority, thus post bronchodilator
readings should be used. Management of stable COPD does often not correspond to guidelines. The IT
system used in this study has the potential to improve diagnosis and management of COPD in primary
care.
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Background
Chronic obstructive pulmonary disease (COPD) is a
growing burden to patients and the National Health Serv-
ice. Disease progression is preventable by early detection
combined with smoking cessation [1,2]. The annual costs
are estimated at £1,639 per patient, 54% of this is for
unscheduled care relating to exacerbations [3]. In primary
care, earlier diagnosis and the use of interventions aimed
at preventing exacerbations and delaying the progression
of the disease may be the best way to tackle these costs [4].
The guidelines of the National Institute for Health and
Clinical Excellence (NICE) on COPD diagnosis and man-
agement [5] are clear and comprehensive. However,
major problems regarding the practical implementation
of these guidelines have been identified that may affect
the accuracy of COPD diagnosis and treatment.
Spirometry is a fundamental component of COPD diag-
nosis [5,6], and can be performed accurately in primary
care [7]. However, some studies have found major prob-
lems with existing spirometry [8-11]. Up to one third of
practices had no spirometer, in addition to which practice
nurses lacked training and support in performing spirom-
etry and interpreting the results [9].
At present, neither the NICE nor the GOLD guidelines rec-
ommend reversibility testing in the diagnosis of COPD.
Post-bronchodilator spirometry is necessary for diagnosis
of COPD according to the GOLD guidelines [6], but not
the NICE guidelines [5].
Reversibility testing using bronchodilators affects the fre-
quency of diagnoses of COPD [12,13]. Prevalence of
COPD was 27% lower using post-bronchodilator spirom-
etry compared to spirometry without bronchodilator [12].
Reversibility testing may also influence treatment deci-
sions. For example, based on a study that used post-bron-
chodilator readings [14], inhaled steroids are
recommended for patients who have a forced expiratory
volume in one second (FEV1) ≤ 50% predicted and two or
more exacerbations per year [5]. Thus, failure to use bron-
chodilators may cause some patients to be given treat-
ment they do not need.
There is widespread evidence of poor adherence to guide-
lines in the management of COPD [15-20]. Studies in pri-
mary care have demonstrated problems with provision of
most treatments including medications, vaccination,
smoking cessation advice and referral to pulmonary reha-
bilitation. For example, 25% of general practitioners
(GPs) systematically prescribed inhaled corticosteroids to
patients with severe COPD, but nearly half of them were
unaware of the guideline-based indication for steroids
[19]. In the United Kingdom, pulmonary rehabilitation is
available to only 2% of those who need it [21]. Provision
of advice on smoking cessation is also poor. Hyland et al.
[22] reported that more than one third of current smokers
with COPD had not been offered help with smoking ces-
sation such as referral to a smoking cessation clinic or
pharmacological therapy.
At present, the quality of diagnosis, assessment and man-
agement of COPD is variable and does not always relate
to the available knowledge about the disease and the bur-
den it represents. The aims of this study were to assess the
diagnostic accuracy of COPD registers in general practice




All practices in the Plymouth area were invited to take
part. The first 13 practices to respond were included. Three
North Devon practices agreed to participate.
Project nurses (Respiratory Specialist Nurses trained and
experienced in primary care management of COPD
including spirometry) collected data from February 2005
to March 2006. Practice registers were electronically
searched using diagnostic codes for COPD. Exclusion cri-
teria were: serious co-morbidity affecting the patient's
ability to take part or to perform spirometry, or inability
to attend the surgery. Records of all patients on the COPD
register were examined and those with coding errors or
normal spirometry were excluded. The remaining suitable
patients were invited to an appointment with the project
nurse.
Audit procedure
The South West Multicentre Research Ethics Committee
confirmed that as a service evaluation, formal research
ethics approval was not required for the audit. Patients
were informed about the study and confidentiality issues.
Patient consent was obtained to collect and analyse the
data using an electronic consent form approved by the
NHS information security and registration authority.
Patient assessment was based on a custom written soft-
ware package. Demographic and clinical data were
entered by the project nurse (Table 1) and questionnaire
data were entered by the patients. Spirometry was per-
formed without bronchodilator therapy in all patients
according to European Respiratory Society and American
Thoracic Society standards [23]. The spirometers used
were a MicroLab ML3500 (Plymouth) and a MicroLab
ML3300 (North Devon). Reversibility testing was per-
formed using 400–800 mcg salbutamol via a large volume
spacer, with spirometry repeated after 15 minutes. In Ply-Respiratory Research 2008, 9:62 http://respiratory-research.com/content/9/1/62
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mouth, reversibility testing was carried out only if clini-
cally indicated to separate asthma from COPD; in North
Devon, reversibility testing was performed on all patients.
After clinical assessments, patients completed on-screen
questionnaires. One question was seen at a time, and each
possible response was numbered. Patients selected their
response and pressed the appropriate number on the key-
board.
Questionnaires included the Medical Research Council
(MRC) Dyspnoea Scale [24], the Clinical COPD Ques-
tionnaire (CCQ) [25] and the Lung Information Needs
Questionnaire (LINQ) [22].
Patients were also asked about their sputum production,
(in order to assess the need for mucolytic therapy), and
whether their symptoms were relieved by short-acting
bronchodilators, (to help assess whether they were receiv-
ing adequate bronchodilator treatment).
Following completion of clinical assessments and ques-
tionnaires, the program automatically determined the
patient's recommended treatment according to the NICE
guidelines. For example, inhaled steroids were recom-
mended if FEV1 was less than 50% predicted and if the
patient had had two or more exacerbations during the pre-
vious year. Recommendations for bronchodilator treat-
ment were based on the nurse's clinical judgement and
whether their current therapy relieved their symptoms
rather than computer logic. Mucolytic therapy was recom-
mended to be considered if the patient had a chronic pro-
ductive cough.
At the end of the assessment, the nurse reviewed the col-
lected data and confirmed the diagnosis. The computer
then produced two separate reports summarising the
results of the assessments; a clinical report for the GP or
practice nurse and a report in layman's terms for the
patient.
The COPD assessment software
The software was revised and improved during the process
of the audit in accordance with feedback from patients,
project nurses and primary care clinicians. Revisions
included requesting data on treatment according to guide-
lines, shortening GP reports, and simplifying patient
reports. As a result of this, there are varying numbers of
patients in the statistical analyses.
Diagnostic criteria
Spirometric results were interpreted according to the
NICE recommendations [5]. If reversibility testing was
applied, diagnosis was based on post-bronchodilator val-
ues. A diagnosis of restriction was given if the FEV1 (%
predicted) was less than 80% and the ratio of FEV1 to
forced vital capacity (FVC) was greater or equal to 0.7.
Asthma was diagnosed on the basis of both spirometric
and clinical features such as the patient's history and fam-
ily history which were obtained from the patient and
examination of their primary care records. Asthma was
confirmed if a patient with airflow obstruction returned to
normal spirometric values or if a large change in FEV1 (>
400 ml) was observed in response to bronchodilators.
Some patients had clinical features of both asthma and
COPD as described in the NICE guidelines.
Table 1: Data gathered by the COPD assessment software (questionnaires not shown)
Demographic data
Weight, height and body mass index (BMI)
Spirometry results: FEV1 and FVC (litres and % of predicted) pre and post bronchodilator
Number of exacerbations in previous year
Number of antibiotics for respiratory tract infections in the previous 12 months
Number of oral steroid courses in the previous 12 months
Number of out of hours visits in the previous 12 months
Number of attendances of Accident and Emergency (A & E) in the previous 12 months
Number of hospital admissions in the previous 12 months
Number of bed days in the previous 12 months
Whether patient had an x-ray at the time of diagnosis or in the previous 5 years
Vaccination status (pneumococcus and influenza)
Current COPD medication: short and long acting bronchodilators, inhaled corticosteroids, mucolytics, other prescribed medications
Inhaler technique: good, moderate, poor
Use of nebuliser
Smoking history: age smoking started, date of cessation, average number of cigarettes per day
Whether patient had undergone smoking cessation treatment
Oxygen assessment and therapy, cor pulmonale, cyanosis
Pulse oximetry value
Attendance of specialist services: respiratory specialist nurse/physiotherapy in the previous 2 years, chest clinic in the previous 5 years, pulmonary 
rehabilitation everRespiratory Research 2008, 9:62 http://respiratory-research.com/content/9/1/62
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Data analysis
Data was transferred into SPSS (Version 14.0, SPSS Inc.,
Chicago IL). Descriptive statistics and cross-tables were
used to evaluate the accuracy of diagnostic registers and
guideline adherence in treatment. If applicable, t tests or
chi square tests were used to analyse between-group dif-
ferences (α = 0.05).
Results
Characteristics of invited and excluded patients
Of the 841 patients invited for assessment, 619 were seen.
Thirty-nine patients (6%) were unable to perform spirom-
etry.
To examine the possibility of selection bias, a sub-sample
of 288 patients on the COPD register were examined in
more detail. Of these patients, 47 (16%) were excluded as
they were unable to attend the practice; the remaining 241
patients were invited. Of these, 43 (18%) patients
declined. No differences in age and gender were seen
between those who attended and those who declined
(Table 2).
Accuracy of diagnostic registers
Of the 580 patients who underwent spirometry, 88 (15%)
patients had normal values, 456 (79%) showed obstruc-
tion, and 36 (6%) showed restriction.
Final diagnoses based on spirometric and clinical features
are shown in Figure 1. Of 580 patients who had spirome-
try, 158 (27%) were found not to have COPD, as per the
NICE guidelines. Of all 422 patients who received the
final diagnosis of COPD, 25 patients (6%) had both
asthma and COPD.
Reversibility testing in patients with airflow obstruction
Airway obstruction was found in 456 patients and revers-
ibility testing was undertaken in 232 (51%). In 140
patients reversibility testing was performed routinely
(North Devon patients) and in 92 patients as clinically
indicated to exclude asthma from COPD (Plymouth
patients).
Reversibility testing led to a change in diagnosis for 25/
232 (11%) patients. Where reversibility testing was per-
formed routinely, the diagnosis changed in 7/140 (5%),
with five being changed from a diagnosis of obstruction to
normal, and two changing from a diagnosis of obstruc-
tion to one of restriction. Where reversibility testing was
performed as clinically indicated, diagnostic changes
occurred in 18/92 (20%) patients, with 14 changing from
a diagnosis of obstruction to normal, and four changing
from a diagnosis of obstruction to restriction.
As regards the magnitude of change in FEV1, 162 patients
(70%) changed by up to 200 ml, 58 patients (25%)
changed by 200–400 ml, and in 12 patients (5%) the
change was larger than 400 ml.
In patients who showed a small change of FEV1 (up to
200 ml), diagnosis was changed in 8/162 (5%). In
patients with a change up to 400 ml, diagnosis was
changed in 12/58 (21%), and in those with a change of
more than 400 ml, diagnosis was changed in 5/12 (42%).
In the large majority of cases the diagnosis was changed
from COPD to asthma. Five of the 12 patients with more
than 400 ml changes in FEV1 through reversibility testing
met the criteria for asthma based on post bronchodilator
readings alone.
The severity grading of airflow obstruction based on pre-
bronchodilator readings changed after bronchodilator in
41/232 (18%) patients. Thirty-one patients changed from
moderate to mild disease, ten from severe to moderate.
Three patients had lower spirometry readings after bron-
chodilators and in these cases their pre-bronchodilator
readings were used to classify severity grading.
Characteristics of patients with confirmed COPD
The cohort of 422 patients with confirmed COPD was
examined further. The mean FEV1 was 1.25 (SD 0.44)
litres and mean FEV1% predicted was 50.3% (SD 14.3).
Based on the NICE guidelines, 227 (54%) patients had
mild COPD, 159 (38%) patients had moderate COPD,
and 36 (9%) patients had severe COPD.
The mean (SD) age was 69.2 (8.7) years. Body mass index
was low (< 18.5) in 26/420 (6%); 32% were normal and
62% were overweight (BMI > 25).
One hundred and thirty-seven patients (33%) were cur-
rent smokers with a mean consumption of 20 cigarettes
per day and an exposure of 48 pack years; 276 (65%) were
ex-smokers with a mean exposure of 43 pack years and ten
patients (2%) had never smoked. Of the current smokers,
76% had been offered help to quit smoking, either with
Table 2: Age and gender of North Devon patients who declined and who were seen
Declined Attended Significance
Age 66.4 (11.3) 68.1 (10.0) t(241) = -0.997, p = 0.320
Gender (Males) 18/43 (42%) 127/198 (64%) X2(1) = 0.27, p = 0.603Respiratory Research 2008, 9:62 http://respiratory-research.com/content/9/1/62
Page 5 of 9
(page number not for citation purposes)
nicotine gum or patches, or by referral to a smoking cessa-
tion clinic.
Exacerbations occurred in all grades of airflow obstruc-
tion. Patients with severe airflow obstruction had received
more steroid courses in the previous year than patients
with milder obstruction. Interestingly, healthcare con-
sumption (out of hours visits, accident and emergency
attendances, bed days spent in hospital) was not particu-
larly skewed towards patients with severe airflow obstruc-
tion (Table 3). Respiratory failure or cor pulmonale was
noted in five patients.
Figure 2 shows counts of MRC dyspnoea scale scores in
the COPD sample, for different degrees of severity. Results
for the LINQ and the CCQ will be reported elsewhere.
In the previous two years, 93/422 (22%) patients had
attended a consultant chest physician; 36/422 (9%)
patients had seen a COPD specialist nurse and 3/422
(0.7%) had seen a respiratory specialist physiotherapist.
In the previous five years, 187/384 (49%) of patients had
had a chest x-ray, at time of diagnosis. Patients who had
attended a consultant chest physician were similar to
those who did not attend in respect of diagnosis and
spirometry: mean FEV1% of predicted was 45.7% (SD
14.8) and 48.5% (SD 13.8) respectively (t = 1.68, p =
0.09), but had higher MRC dyspnoea scores: median 3.1
(IQR 1.3) and 2.7 (IQR 1.50), p = 0.002. No differences
were noted between those attending and those not attend-
ing secondary care were noted with respect of age, smok-
ing status, pack years or in the proportions that were on
the recommended treatment with short and long acting
Final diagnoses in the Plymouth COPD audit sample Figure 1
Final diagnoses in the Plymouth COPD audit sample.
Table 3: Frequency of exacerbations, antibiotic and steroid courses and healthcare consumption in patients with confirmed COPD
Number in previous year of: Mild (N = 226) Moderate (N = 158) Severe (N = 36) All (N = 420)
Exacerbations 1.3 (1.7) 1.3 (1.6) 1.7 (2.3) 1.4 (1.8)
Antibiotics courses 1.2 (1.6) 1.3 (1.6) 1.7 (2.3) 1.3 (1.6)
Steroid courses 0.7 (1.3) 0.7 (1.4) 1.4 (2.2) 0.8 (1.4)
Out of hours visits 0.1 (0.4) 0.2 (0.5) 0.2 (0.8) 0.1 (0.5)
Attended A&E 0.1 (1.1) 0.1 (0.5) 0.2 (0.5) 0.1 (0.9)
Bed days 0.5 (3.0) 0.8 (4.0) 0.7 (2.4) 0.6 (3.3)Respiratory Research 2008, 9:62 http://respiratory-research.com/content/9/1/62
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anti-cholinergic, long acting beta-2-agonists inhaled ster-
oids or mucolytics therapies.
Management of COPD and compliance with guidelines
Data on current or recommended treatment were availa-
ble for 278 of the 422 patients diagnosed with COPD
(Table 4).
Long acting bronchodilators were recommended for more
patients than had received them and were therefore under
prescribed. The NICE guidelines recommend that muco-
lytic therapy should be considered in patients with a
chronic cough productive of sputum. Although 53% had
a chronic productive cough, only 4% of these were receiv-
ing mucolytics. By contrast, 60% of patients were receiv-
ing inhaled steroids, of which only 23% met the
indication of FEV1, less than 50% of predicted and two or
more exacerbations per year [5]. Nine patients for whom
inhaled steroids would be recommended had not received
Distribution of MRC dyspnoea score for different degrees of severity of airflow obstruction Figure 2















Table 4: Current and recommended treatment in patients with confirmed COPD and proportion of patients in whom a treatment was 
recommended who were receiving that treatment
No. currently receiving 
the treatment
No. for whom the treatment 
was recommended
No. receiving the treatment 
recommended for them
(N = 278) (N = 278) (N = 278)
SAAC 124 (44.6%) 109 (39.2%) 59/109 (54%)
LAB2 agonists 124 (44.6%) 80 (28.8%) 37/80 (46%)
LAAC 50 (18.0%) 53 (19.1%) 12/53 (23%)
Inhaled steroids 167 (60.0%) 48 (17.0%) 39/48 (81%)
Mucolytics 9 (3%) 144 (53.0%) 6/144 (4%)Respiratory Research 2008, 9:62 http://respiratory-research.com/content/9/1/62
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them, again highlighting the problem of inappropriate
prescribing.
Practices varied substantially in prescribing long acting
bronchodilators. The proportion of patients prescribed
long acting beta-2-agonists ranged between 23–56% in
different practices, and between 9–25% for long acting
anticholinergics.
Prescribing outside of licensed indications was noted in
six patients who were taking short acting anticholinergics
and long acting anticholinergics therapy at the same time.
Although long acting anticholinergics are only licensed
for use in COPD, six patients who were found not to have
COPD were on long acting anticholinergics.
Vaccination status was recorded for immunisation against
pneumococcus and influenza, both of which are recom-
mended in COPD. Influenza vaccine was up to date in
346/398 (87%) and pneumococcal vaccination was up to
date in 227/380 (60%).
Data on attendance or recommendation to attend pulmo-
nary rehabilitation were available for 372 COPD patients.
Recommendations were based on the NICE guidelines
which state that "Pulmonary rehabilitation should be
offered to all those who consider themselves functionally
disabled by COPD (usually MRC dyspnoea scale score of
three and above)" [5].
Pulmonary rehabilitation was not available in North
Devon, but 54/134 (40%) North Devon patients had an
MRC dyspnoea scale score of three or more. None of these
patients had attended pulmonary rehabilitation. In Ply-
mouth, 121/238 (51%) had MRC dyspnoea scale score of
three or more and 80/238 patients (34%) were willing,
suitable and able to take part. Of these, five had an
MRCDS score of less than three and 7/80 (9%) had
attended rehabilitation.
Discussion
COPD is an important disease that compromises patients'
quality of life and creates a huge financial burden to the
National Health Service. Our study confirms that disease
management takes place largely in primary care. Guide-
lines suggest that an accurate diagnosis should be fol-
lowed by effective treatments of stable disease and
exacerbations of COPD.
Diagnostic registers have inherent problems. According to
the present findings, registers include large numbers with-
out COPD. In this study, 27% of individuals listed as hav-
ing COPD were eligible for reclassification of their disease
following structured clinical assessment by a trained
nurse. These findings confirm the problems previously
observed with application and interpretation of spirome-
try in primary care.
The application of reversibility testing is a controversial
issue in the diagnosis of COPD in primary care [26].
Recent guidelines have suggested that reversibility testing
should be used where clinically indicated to separate
asthma from COPD [5,6], but there is a lack of good evi-
dence to underpin these recommendations [26]. Reversi-
bility testing records the change in FEV1 before and after
bronchodilators and the magnitude of this change has
been used to differentiate asthma from COPD [5,27].
Reversibility testing was found to change the diagnosis
from that made on pre-bronchodilator spirometry in 11%
of cases. This finding demonstrates the benefits of judi-
cious use of reversibility testing based on clinical need to
exclude asthma as opposed to performing reversibility
testing in all cases. This study confirms that performing
pre-bronchodilator spirometry alone leads to overestima-
tion of the prevalence and severity of COPD, with the
potential to cause errors in treatment. The use of pre-bron-
chodilator spirometry alone cannot be recommended for
diagnosis and severity assessment-spirometry in primary
care should be done only after administration of bron-
chodilators. This approach is in keeping with the current
GOLD guidelines, whereas the NICE guidelines do not
specify the importance of post-bronchodilator readings.
This study examined current treatment against treatment
as recommended by the NICE guidelines. Under-prescrib-
ing with bronchodilators, particularly long acting agents
was apparent. Long acting bronchodilators are known to
improve lung function, exercise tolerance, symptoms, and
quality of life, and to reduce exacerbations [6]. Further-
more, it is known that bronchodilators interact with other
treatments to improve outcomes. The combination of flu-
ticasone and salmeterol reduced decline in lung function
over 3 years, [28] and outcomes in pulmonary rehabilita-
tion were improved by tiotropium [29]. The reason why
these drugs are not prescribed may be due to concerns
over price, a lack of knowledge about the benefits of these
medicines [19] or from an unjustified nihilistic approach
to COPD management [30]. There was no evidence that
this phenomenon was limited to primary care, those
attending a consultant chest physician in the previous five
years were no more likely to be treated according to guide-
lines.
This study highlights an apparent over-treatment with
inhaled steroids. Only a minority of those who received
inhaled steroids met the NICE criteria. In some cases,
treatment with steroids may once have been not only
appropriate, but also effective in reducing exacerbations
until they were no longer appeared necessary. Over-treat-Respiratory Research 2008, 9:62 http://respiratory-research.com/content/9/1/62
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ment suggests a waste of resources and puts patients at risk
of adverse effects. These findings concur with Decramer et
al. [15], who revealed that 49% of GPs prescribed inhaled
steroids to all of their COPD patients. The role of muco-
lytics is debated [31], but despite the evidence-based rec-
ommendations in NICE that mucolytics should be
considered in patients with a chronic productive cough,
mucolytics are seldom prescribed to such patients.
Quitting smoking improves patients' prognoses in COPD,
and offering support to stop smoking reduces mortality
and morbidity from COPD [1]. It is disappointing that a
quarter of current smokers with COPD had not been
offered practical help in terms of referral to smoking ces-
sation service or drug therapy. While patients may not
accurately report the help they have been offered, Rut-
schmann et al. [19] found that many physicians reported
feeling uncomfortable giving smoking cessation advice,
and a fifth of physicians were unaware that smoking ces-
sation had a positive impact on life expectancy and dis-
ease progression.
Pulmonary rehabilitation is highly effective and is a cost
effective intervention recommended by national and
international COPD guidelines. The finding in this study
was striking-in certain geographic regions pulmonary
rehabilitation was not available at all and where it was
available, only 9% of eligible patients had attended. Iden-
tification of patients suitable for rehabilitation is an
important component of COPD assessment, as currently
the proven benefits of pulmonary rehabilitation are being
denied to many patients.
This study used a novel information technology system
that provides a systematic and comprehensive assessment
package for COPD, and facilitates the delivery of high-
quality care according to guidelines. The system assesses
clinical data and examines patient-centred outcomes such
as quality of life and patients' perceived information
needs. By providing reports to both GPs and patients it
offers a new approach to COPD management in primary
care. Management according to the guidelines is pro-
moted with the potential to improve care. The system also
has an educational function as GPs and nurses are given
the opportunity to learn about COPD management.
Given these advantages, use of the system has the poten-
tial to enable long-term improvement of COPD manage-
ment. However, using a different IT-system for guideline-
based management of COPD and asthma, Tierney et al.
[32] reported no enhanced adherence to guidelines and
no beneficial effects on patient-centred and clinical out-
comes over a year. Research into the benefits of our system
in terms of long-term improvement of clinical care and
patient-centred outcomes is ongoing.
This study has some limitations. Although the participat-
ing practices provided a spectrum of COPD services and
varied widely in their size and socio-demographic fea-
tures, they may not representative as they were all in
Devon and were included on the basis of their interest in
the project. Furthermore, as only patients who were able
to attend primary care clinics were included, those most
severely affected by their COPD and those with important
co-morbidities may have been under-represented.
The software system made recommendations for specific
treatments based on guidelines and some recommenda-
tions were not definite statements that the treatment was
required, but that the treatment should be considered,
(for example mucolytics therapy). Thus the apparent
under-prescribing in these situations is more difficult to
interpret and may be appropriate use of therapy. A further
limitation was that this was a cross-sectional study and
did not assess the impact of recommendations on chang-
ing treatment or other outcomes. The actual decision by
the GP to prescribe, the patients' compliance, response to
treatment and duration were outside the scope of the
study. The software system had not been formally vali-
dated in other studies.
Conclusion
The present study represents one of the first studies to
report the true levels of severity of COPD and the provi-
sion of appropriate treatments in primary care. The study
demonstrates that compared to diagnoses made by expert
nurses with the help of a standardised, guideline-based
computer program, the diagnostic registers in primary
care are inaccurate in 27% of cases. The role of reversibil-
ity testing was examined and it was found that pre-bron-
chodilator readings alone overestimated both prevalence
and the severity of COPD. Reversibility testing was useful
in detecting some cases where a diagnosis of asthma was
considered. On this basis it is suggested that only post
bronchodilator readings should be used routinely in pri-
mary care, but reversibility testing is appropriate in spe-
cific cases where asthma is suspected. The management of
patients with COPD seldom followed guideline based rec-
ommendations in terms of drug treatment and pulmo-
nary rehabilitation.
In the future, computer-based assessment systems which
provide management recommendations may facilitate
optimal diagnosis and treatment for patients with COPD
in primary care.
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